Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2003

View Archived Issues

SBIR grant to fund investigation of Triapine's antiviral activity

BMS obtains license to Elan NanoCrystal technology

ViroPharma awarded SBIR grants to support biodefense effects

Avecia awarded anthrax vaccine contract by NIAID

Antiinflammatory effects of Ono-6126 in healthy volunteers

Potential benefits reported for the anticonvulsant vigabatrin in cocaine addiction

Improved lung function in asthmatics after treatment with roflumilast

Pregabalin in generalized anxiety disorder

New MMP inhibitors and their use reported by British Biotech and Serono researchers

Novel lipase inhibitors prepared and tested by Aventis scientists

Two series of antibacterial oxazolidinones with decreased MAO activity presented by AstraZeneca

Pharmacia (now Pfizer) claims new IKK-2 inhibitors for cancer and inflammation

Pfizer team identifies new glycogen phosphorylase inhibitors for diabetes and related disorders

New xanthine oxidase inhibitors described in Fuji Yakuhin patent

Actelion to acquire Axovan, obtaining rights to clazosentan

Barr to acquire Plan B emergency contraceptive

Chiron gains certain development and commercialization rights to Cubicin

Pivotal ocinaplon trial on hold pending additional safety information

Orion to withdraw German filing for Simdax and resubmit at later date

6-Aminouracil DNA polymerase IIIC inhibitors as new antibacterial agents

Hybrid antibacterial agents with dual oxazolidinone and quinolone properties

Chiron designs potent ketolide antibacterial agents

VIC-200603: a ramoplanin derivative with good local tolerability following systemic administration

Inhaled AWD-12-281 exerts potent bronchodilating effects in animal model of asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...